Kala Pharmaceuticals (KALA) Receiving Somewhat Favorable Media Coverage, Study Shows

News articles about Kala Pharmaceuticals (NASDAQ:KALA) have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kala Pharmaceuticals earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.1745916959157 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

KALA has been the topic of several analyst reports. BidaskClub downgraded Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 1st. ValuEngine raised Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Wedbush reaffirmed an “outperform” rating and set a $47.00 price target on shares of Kala Pharmaceuticals in a research report on Wednesday, June 20th. Finally, Zacks Investment Research raised Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $36.00.

Get Kala Pharmaceuticals alerts:

Shares of NASDAQ:KALA traded down $0.17 during trading on Monday, reaching $13.13. 308,600 shares of the company’s stock traded hands, compared to its average volume of 249,898. Kala Pharmaceuticals has a fifty-two week low of $11.81 and a fifty-two week high of $26.75. The company has a quick ratio of 20.40, a current ratio of 20.40 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $326.68 million and a PE ratio of -2.25.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its earnings results on Thursday, May 10th. The company reported ($0.46) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.46). sell-side analysts expect that Kala Pharmaceuticals will post -1.97 earnings per share for the current fiscal year.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.